Attovia Therapeutics priced an upsized IPO to raise $289 million, extending a streak of large biotech offerings and funding expansion of its immunology and inflammation portfolio into 2027. The company’s raised capital is intended to support clinical development and broaden manufacturing capacity as it scales its next-stage programs. The transaction underscores continued investor appetite for late preclinical-to-clinical immunology candidates with clear differentiation narratives, even as other sectors show pockets of volatility in valuations and follow-on financing.